Compare Cognizant Technology Solutions Corp (CTSH) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs GeneDx Holdings Corp — how do they compare? Cognizant Technology Solutions Corp trades at $59.2 (market cap $27.03B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Cognizant Technology Solutions Corp is far larger — about 13.4× GeneDx Holdings Corp's market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and GeneDx Holdings Corp for 19 Days on average.
| CTSH | WGS | |
|---|---|---|
Market Cap | $27.03B | $2.02B |
Volume | 9,883,888 | 734,640 |
Sector | Technology | Health |
52-Week High | $86.70 | $167.51 |
52-Week Low | $38.73 | $34.51 |
Typical Hold Time | 57 Days | 19 Days |
Enterprise Value | $28.08B | $2.05B |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTSH trades at $60.01, up 5.15% with a bullish technical signal. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed. The company shows solid fundamentals with a P/E of 12.88 and net income margin of 10.26%. Positive news includes AI partnerships and employer awards, supporting investor confidence.
The outlook is positive with a consensus price target of $64.25, indicating potential upside. Risks include competitive pressures in IT services and reliance on AI adoption. Strong cash flow and low debt bolster stability, but market volatility and economic headwinds remain concerns for sustained growth.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
